Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation.
Luk SJ, Schoppmeyer R, Ijsselsteijn ME, Somarakis A, Acem I, Remst DFG, Cox DT, van Bergen CAM, Briaire-de Bruijn I, Grönloh MLB, van der Meer WJ, Hawinkels LJAC, Koning RI, Bos E, Bovée JVMG, de Miranda NFCC, Szuhai K, van Buul JD, Falkenburg JHF, Heemskerk MHM. Luk SJ, et al. Among authors: remst dfg. Cancer Immunol Res. 2023 Nov 1;11(11):1480-1492. doi: 10.1158/2326-6066.CIR-22-0759. Cancer Immunol Res. 2023. PMID: 37695550
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
Meeuwsen MH, Wouters AK, Jahn L, Hagedoorn RS, Kester MGD, Remst DFG, Morton LT, van der Steen DM, Kweekel C, de Ru AH, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: remst dfg. Mol Ther. 2022 Feb 2;30(2):564-578. doi: 10.1016/j.ymthe.2021.08.010. Epub 2021 Aug 8. Mol Ther. 2022. PMID: 34371177 Free PMC article.
An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML.
van der Lee DI, Koutsoumpli G, Reijmers RM, Honders MW, de Jong RCM, Remst DFG, Wachsmann TLA, Hagedoorn RS, Franken KLMC, Kester MGD, Harber KJ, Roelofsen LM, Schouten AM, Mulder A, Drijfhout JW, Veelken H, van Veelen PA, Heemskerk MHM, Falkenburg JHF, Griffioen M. van der Lee DI, et al. Among authors: remst dfg. Cancers (Basel). 2021 Oct 27;13(21):5390. doi: 10.3390/cancers13215390. Cancers (Basel). 2021. PMID: 34771556 Free PMC article.
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure.
Wachsmann TLA, Wouters AK, Remst DFG, Hagedoorn RS, Meeuwsen MH, van Diest E, Leusen J, Kuball J, Falkenburg JHF, Heemskerk MHM. Wachsmann TLA, et al. Among authors: remst dfg. Oncoimmunology. 2022 Feb 1;11(1):2033528. doi: 10.1080/2162402X.2022.2033528. eCollection 2022. Oncoimmunology. 2022. PMID: 35127255 Free PMC article.
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
van Amerongen RA, Hagedoorn RS, Remst DFG, Assendelft DC, van der Steen DM, Wouters AK, van de Meent M, Kester MGD, de Ru AH, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: remst dfg. J Immunother Cancer. 2022 Jun;10(6):e004409. doi: 10.1136/jitc-2021-004409. J Immunother Cancer. 2022. PMID: 35728869 Free PMC article.
22 results